Acute oxaliplatin-induced peripheral nerve hyperexcitability

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1767-1774

  Wilson, Richard H ^a   Lehky, Tanya ^a   Thomas, Rebecca R ^a   Quinn, Mary G ^a   Floeter, Mary Kay ^a   Grem, Jean L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBAMAZEPINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MYOKYMIA; NERVE CONDUCTION; NERVE EXCITABILITY; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

ACUTE DISEASE; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAMAZEPINE; CLINICAL TRIALS, PHASE I; DEOXYCYTIDINE; ELECTROMYOGRAPHY; FEMALE; HUMANS; ISAACS SYNDROME; MALE; MIDDLE AGED; NEURAL CONDUCTION; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT FAILURE;

EID: 0036534144     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.056     Document Type: Article

References (33)

1. Oxaliplatin: A review of preclinical and clinical studies
2. Clinical efficacy of oxaliplatin monotherapy. Phase II trials in advanced colorectal cancer
3. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer
4. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
5. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer
6. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistance cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
7. Antitumour activity of oxaliplatin in neuroblastoma cell lines
8. Oxalato-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
9. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
10. Cisplatin neurotoxicity
11. Phase I study of oxaliplatin in patients with advanced cancer
12. Oxaliplatin (L-OHP): Global safety in 682 patients
13. Thalidomide neuropathy in patients treated for metastatic prostate cancer
14. Diseases associated with excess motor unit activity
15. Acquired neuromyotonia: A new autoantibody-mediated neuronal potassium channelopathy
16. A syndrome of continuous muscle fiber activity
17. Neuromyotonia in mice with hereditary myelinopathies
18. Gold neurotoxicity and myokymia
19. Penicillamine-induced neuromyotonia
20. Differences in behaviour of sensory and motor axons following release of ischaemia
21. Strength-duration properties of peripheral nerve in acquired neuromyotonia
22. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia
23. Potassium current suppression in patients with peripheral nerve hyperexcitability
24. Understanding neuromyotonia
25. Clinical pharmacokinetics of oxaliplatin: A critical review
26. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons
27. Carbamazepine and 10, 11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture
28. Antiepileptic drug mechanisms of action
29. Effects of carbamazepine on nerve activity and transmitter release in neuroblastoma-glioma hybrid cells and the frog neuromuscular junction
30. Oxaliplatin-induced neuropathy: Could gabapentin be the answer
31. Prevention of oxaliplatin induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer
32. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs